Latest revenue
—
as of —
Latest net income
—
as of —
Net margin
—
as of —
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $170.1M
- Enterprise value
- $170.1M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $5.38
- 52-wk low
- $1.91
- Beta
- —
- Shares out
- 40.4M
5-year trend
What this company does
Item 1. Business Overview OnKure Therapeutics, Inc. (“OnKure”, “we”, “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases that are underserved by available therapies. Using a structure-based drug design platform, we are committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to achieve optimal efficacy and tolerability by selectively targeting specific mutations shown to be key drivers of cancer and other diseases. By selectively sparing the wild-type enzyme and preferentially targeting…
AI summary unavailable — showing raw filing excerpt
Generated from OKUR's filing dated 2026-03-12
Key risks
RISK FACTORS An investment in shares of our Class A Common Stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before deciding whether to purchase, hold or sell shares of our Class A Common Stock. The occurrence of any of the risks described below could harm our business, financial condition, results of operations, growth prospects, and/or stock price or cause our actual results to differ materially from those contained in…
AI summary unavailable — showing raw filing excerpt
Generated from OKUR's filing dated 2026-03-12
Profitability
Operating margin
-1833.7%
42.2%Net margin
-1733.7%
43.6%Return on equity
-105.9%
108.8%Return on assets
-95.8%
109.0%Leverage
Debt / equity
0.11×
1.0%Debt / assets
9.6%
0.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-15.2M | +4.8% | — |
Q4 2025 2025-12-31 | — | — | $-13.5M | +61.6% | — |
Q3 2025 2025-09-30 | — | — | $-14.7M | -298.1% | — |
Q2 2025 2025-06-30 | — | — | $-15.4M | -187.1% | — |
Q1 2025 2025-03-31 | — | — | $-15.9M | -89.0% | — |
Q4 2024 2024-12-31 | — | — | $-35.2M | — | — |
Q3 2024 2024-09-30 | — | — | $-3.7M | +80.8% | — |
Q2 2024 2024-06-30 | — | — | $-5.4M | +72.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on OKUR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$4.7K
Net activity
−$4.7K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns OKUR
Institutional value
$4.6M
Total shares held
1.1M
Distinct holders
15
-28 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 582.5K | $2.4M | — | New |
| 2 | Carlyle Group Inc. | 269.9K | $1.1M | +0 (+0.0%) | No change |
| 3 | Aisling Capital Management LP | 88.6K | $366.8K | +0 (+0.0%) | No change |
| 4 | BlackRock, Inc. | 49.6K | $205.3K | -3.1K (-5.9%) | Trimmed |
| 5 | VANGUARD FIDUCIARY TRUST CO | 43.4K | $179.6K | — | New |
| 6 | Aldebaran Capital, LLC | 40.4K | $167.3K | -865 (-2.1%) | Trimmed |
| 7 | JANE STREET GROUP, LLC | 26.8K | $111.0K | +7.4K (+38.1%) | Added |
| 8 | WELLS FARGO & COMPANY/MN | 13.5K | $55.9K | +2.5K (+22.7%) | Added |
| 9 | UBS Group AG | 3.4K | $14.1K | +2.2K (+181.0%) | Added |
| 10 | Vanguard Global Advisers, LLC | 745 | $3.1K | — | New |
| 11 | BNP PARIBAS FINANCIAL MARKETS | 281 | $1.2K | +0 (+0.0%) | No change |
| 12 | TRUST CO OF TOLEDO NA /OH/ | 136 | $563 | +0 (+0.0%) | No change |
| 13 | JPMORGAN CHASE & CO | 45 | $171 | -500 (-91.7%) | Trimmed |
| 14 | GSA CAPITAL PARTNERS LLP | 22.2K | $92 | -23.7K (-51.6%) | Trimmed |
| 15 | CITIGROUP INC | 1 | $4 | -3.7K (-100.0%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once OKUR's latest filing finishes processing.